UTERINE MYXOID LEIOMYOSARCOMA AND CYVADIC-ETOPOSIDE THERAPY

被引：8

作者：

FUKUNISHI, H ^{[1
]}

YUKIMURA, N ^{[1
]}

TAKEUCHI, S ^{[1
]}

KITAZAWA, S ^{[1
]}

机构：

[1] KOBE UNIV,SCH MED,DEPT PATHOL,KOBE 650,JAPAN

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS | 1994年 / 46卷 / 03期

关键词：

MYXOID LEIOMYOSARCOMA; MITOTIC COUNT; CYVADIC-ETOPOSIDE CHEMOTHERAPY;

D O I：

10.1016/0020-7292(94)90413-8

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Objectives: To conduct a pathological characterization of rare uterine myxoid leiomyosarcoma (MLS) and establish an effective chemotherapy for metastasis after hysterectomy. Methods: Histological and immunohistochemical methods were used to characterize the type of uterine MLS in a 39-year-old female. For multiple lung metastases found 3 months after operation, CYVADIC (400 mg cyclophosphamide, 1 mg vincristine, 50 mg epirubicin and 400 mg dacarbazine per body for one course) and oral etoposide (50 mg/body per day for 2 weeks) were applied. Results: The rapidly enlarging uterine tumors exhibited gelatinous cut surfaces, a high count of 30 mitotic cells per 10 hpf and mucinous stroma, indicating a rare high-mitotic type of uterine MLS. The two-course CYVADIC-etoposide therapy was effective for disseminated pulmonary metastases. Conclusion: The present MLS was a rare high-mitotic type. CYVADIC-etoposide was an optional effective chemotherapy for lung metastasis in this case.

引用

页码：321 / 324

页数：4

共 6 条

[1]

CHEN KTK, 1984, INT J GYNECOL PATHOL, V3, P389

[2] MYXOID LEIOMYOSARCOMA OF THE UTERUS - A REPORT OF 6 CASES [J].